Consensus Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
5.63 ^USD	-3.43%		+0.18%	-44.42%

May. 14	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	MT
May. 09	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	MT

Evolution of the average Target Price on Editas Medicine, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ddbed08bbe79949a0d77bfdb845c.OzyB7-CscUedd34c312UsaAqO-56x3DaVy-rShSh3iI.f1TxjNGdJQvkODB6kQrX_ZB8VqQxhD2zIEHofFHn71R2Y9mEr50lDM4fJw~8855bf84d900d5ccb8901bdf80d41c97

Analyst Recommendations on Editas Medicine, Inc.

Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	May. 14	MT
Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	May. 09	MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	May. 09	MT
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	Feb. 29	MT
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating	Jan. 03	MT
Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating	Dec. 12	MT
Citigroup Upgrades Editas Medicine to Buy From Neutral, Price Target is $11	23-10-24	MT
ANALYST RECOMMENDATIONS : Dollar General, On Holding, Rio Tinto, Solaredge, Thermo Fisher...	23-10-24
JPMorgan Upgrades Editas Medicine to Neutral From Underweight, Price Target is $8	23-10-18	MT
Stifel Upgrades Editas Medicine to Buy From Hold, Adjusts Price Target to $17 From $9	23-09-29	MT
Chardan Cuts Price Target on Editas Medicine to $19 From $22, Maintains Buy Rating	23-08-03	MT
Raymond James Upgrades Editas Medicine to Outperform From Market Perform, Price Target is $17	23-06-13	MT
Credit Suisse Trims Editas Medicine's Price Target to $14 From $15, Keeps Neutral Rating	23-05-08	MT
RBC Lifts Price Target on Editas Medicine to $8 From $7, Maintains Sector Perform, Speculative Risk	23-05-08	MT
RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating	23-04-06	MT
Credit Suisse Raises Editas Medicine's Price Target to $15 From $13, Keeps Neutral Rating	23-02-23	MT
Chardan Adjusts Price Target on Editas Medicine to $22 From $35, Maintains Buy Rating	23-02-23	MT
Cantor Fitzgerald Starts Editas Medicine at Overweight With $15 Price Target	23-02-01	MT
Morgan Stanley Adjusts Editas Medicine's Price Target to $7 From $8, Keeps Underweight Rating	23-01-24	MT
SVB Securities Adjusts Price Target on Editas Medicine to $7 From $6, Maintains Market Perform Rating	23-01-23	MT
SVB Securities Trims Price Target on Editas Medicine to $6 From $7, Maintains Market Perform Rating	23-01-10	MT
Wells Fargo Adjusts Price Target on Editas Medicine to $36 From $50, Maintains Overweight Rating	23-01-04	MT
Citigroup Initiates Coverage on Editas Medicine With Neutral Rating, $11 Price Target	22-12-13	MT
Fears of Rate Hike Easing Delay Subdue Exchange-Traded Funds, Stock Futures Premarket Tuesday	22-12-06	MT
Credit Suisse Assumes Coverage of Editas Medicine at Neutral With $13 Price Target, Sees Little Value From Lead Asset EDIT-301	22-12-06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.63 USD

Average target price

15.13 USD

Spread / Average Target

+168.80%

High Price Target

27 USD

Spread / Highest target

+379.57%

Low Price Target

7 USD

Spread / Lowest Target

+24.33%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Editas Medicine, Inc.

Barclays
Morgan Stanley
RBC Capital Markets
Truist Securities
Citigroup
JPMorgan Chase
Stifel Nicolaus
Chardan Research
Raymond James
Credit Suisse
Cantor Fitzgerald
SVB Securities LLC
Wells Fargo Securities
BofA Securities
Baird
Oppenheimer
Goldman Sachs
SVB Leerink
Evercore ISI
Chardan
J.P. Morgan Chase

Ratings for Editas Medicine, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar